Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DME2H5T)

Drug Name
Cilastatin Drug Info
Synonyms
Cilastatina; Cilastatine; Cilastatinum; Cilastatin Monosodium Salt; Cilastatin acid; Cilastatina [Spanish]; Cilastatine [French]; Cilastatinum [Latin]; MK0791; Cilastatin (INN); Cilastatin [INN:BAN]; MK-791; (2Z)-7-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-2-({[(1S)-2,2-dimethylcyclopropyl]carbonyl}amino)hept-2-enoic acid; (Z)-(S)-6-carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteine; (Z)-7-[(2R)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid
Therapeutic ClassAntibiotics
Cross-matching ID
PubChem CID
6435415
ChEBI ID
CHEMBL766
CAS Number
CAS 82009-34-5
TTD Drug ID
D02GIU
VARIDT Drug ID
DR00505

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mismatch repair 2.21 0.00e+0 22/23 (95.65%) EXO1;MSH6;MLH1;...
Ribosome 2.12 0.00e+0 113/158 (71.52%) RPS4Y1;RPS5;RPL29;...
DNA replication 2.01 2.18e-3 34/36 (94.44%) MCM7;PCNA;RFC2;...
Fanconi anemia pathway 1.92 3.26e-3 36/54 (66.67%) FANCI;BLM;PALB2;...
Citrate cycle (TCA cycle) 1.82 1.96e-2 30/30 (100%) SUCLG2;PDHA1;SUCLG1;...
Coronavirus disease 1.81 1.85e-2 215/232 (92.67%) RPS4Y1;MX1;RPS5;...
Ribosome biogenesis in eukaryotes 1.77 2.43e-2 52/108 (48.15%) RPP38;POP5;PWP2;...
TGF-beta signaling pathway 1.75 2.20e-2 81/94 (86.17%) ID3;BMP2;ID4;...
Mineral absorption 1.74 2.18e-2 48/60 (80%) MT1E;MT1G;MT1H;...
Cell cycle 1.65 4.64e-2 110/124 (88.71%) CDK6;SMAD3;CDC45;...
mTOR signaling pathway -1.67 4.62e-2 114/154 (74.03%) TNFRSF1A;ATP6V1F;LAMTOR3;...
Mitophagy -1.68 4.44e-2 56/68 (82.35%) ATG9A;MFN1;BNIP3;...
Autophagy -1.71 3.62e-2 113/169 (66.86%) ATG9A;ATG16L1;BNIP3;...
Salivary secretion -1.71 3.44e-2 76/93 (81.72%) ATP1B2;CST3;ADCY8;...
Glutamatergic synapse -1.72 3.58e-2 97/114 (85.09%) HOMER2;HOMER1;ADCY9;...
Pancreatic secretion -1.73 3.65e-2 87/102 (85.29%) ADCY9;ITPR3;PLA2G1B;...
Leukocyte transendothelial migration -1.74 3.53e-2 90/114 (78.95%) MYL12B;ACTN4;CTNNA2;...
Protein processing in endoplasmic reticulum -1.79 2.07e-2 127/171 (74.27%) MAN1C1;MAN1A2;PDIA3;...
Endocrine and other factor-regulated calcium reabsorpti... -1.83 1.31e-2 49/53 (92.45%) ADCY9;KL;SLC8A2;...
Ferroptosis -1.90 5.24e-3 36/41 (87.8%) SLC39A14;SLC3A2;CYBB;...
Bile secretion -1.92 4.37e-3 68/90 (75.56%) SCT;ADCY9;ABCG2;...
Lysosome -1.93 4.91e-3 115/128 (89.84%) GLA;GLB1;CD68;...
Vibrio cholerae infection -1.95 5.61e-3 44/50 (88%) ATP6V1F;ADCY9;SEC61A1;...
IL-17 signaling pathway -1.99 4.37e-3 84/94 (89.36%) IKBKE;CSF3;TBK1;...
Rheumatoid arthritis -1.99 5.24e-3 78/93 (83.87%) CD86;CTSL;LTB;...
Estrogen signaling pathway -2.09 0.00e+0 119/137 (86.86%) CALML5;HSP90AB1;CREB3L1;...
Steroid biosynthesis -2.10 0.00e+0 19/20 (95%) LSS;FDFT1;HSD17B7;...
Collecting duct acid secretion -2.11 0.00e+0 22/27 (81.48%) SLC4A1;ATP6V1F;ATP6V0A4;...
Synaptic vesicle cycle -2.13 0.00e+0 63/78 (80.77%) SLC1A2;SLC17A6;DNM2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 10uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H